How to invest in AI startups in 2026: access, SPVs and the real risks

Artificial intelligence is the defining private-market theme of the decade. That much is not in dispute. The models are improving, the revenue lines of a few companies are growing at speeds rarely seen, and capital is flooding towards anything with the label attached. If you have money and an interest in private markets, the pull towards AI is entirely rational.

The problem is not conviction. It is access. The distance between wanting to invest in AI and actually being allowed into a round is enormous, and most writing on the subject skips over that distance as if it were a formality. It is not. Access is the whole game — and it is where we will spend most of this piece, including the parts that are uncomfortable.

Why AI is the theme — and why access is the true bottleneck

Every cycle has a story that pulls capital towards it. This one is AI, and for once the story is grounded in visible progress rather than pure imagination. A handful of companies have built models that people pay for, that businesses are wiring into their operations, and that improve on a schedule investors find hard to ignore. As of early 2026, the most prominent private AI companies carry some of the highest valuations ever attached to private businesses.

That gravity creates a strange market. There is no shortage of money wanting in. What is scarce is allocation — the right to put your money into a specific round. When a leading model company raises, the round is spoken for by the time it is announced. The founders choose their investors, not the other way around. Strategic partners who supply compute, sovereign wealth funds, and a short list of venture firms with existing relationships fill it. The cheque size that gets you a seat is enormous, and even that is not enough without the relationship.

So the question that matters in "how to invest in AI startups" is not "which company should I pick?" It is "which door can I actually get through, and what does it cost me in fees, risk and liquidity to use it?"

In this cycle, the scarce asset is not a good AI company. It is a seat in the round. Everything else is a consequence of that.

The five ways into private AI

Set aside the fantasy of buying OpenAI shares on your phone. Here are the routes that genuinely exist, from the most hands-on to the most delegated, plus the public alternative most people default to.

1. Angel direct

You invest your own money straight into an early-stage AI company, onto its cap table. This is the purest form of access and the hardest to arrange. It requires deal flow — knowing founders who are raising — credibility that makes a founder want you on the register, and usually accredited or professional investor status. For the vast majority of people, the earliest, most interesting AI companies are simply not reachable this way. When they are reachable, you are typically backing a very young company where the failure rate is highest.

2. Syndicates and SPVs

A syndicate aggregates a group of investors into a single-deal vehicle — a special purpose vehicle — that invests as one line on the cap table. This is how most individuals get into a specific private AI round without needing their own founder relationships or a seven-figure cheque. A lead sources the allocation, structures the SPV, and invites members in. You see the company before you commit, and you share economics with the group. The trade is fees, usually a set-up cost plus carried interest, and the same concentration and illiquidity as any single-company bet. This is the model we run at Allocation10, one deal at a time. (We wrote a plain-English guide to how SPVs work if you want the mechanics.)

3. Venture and growth funds

You commit capital to a fund whose managers pick and hold private AI positions across a portfolio. You get diversification and professional selection, but you delegate every decision, you cannot see the specific companies before committing, and you typically lock up a large sum for years. Access to the best funds is itself competitive — the strongest managers are often closed to new investors. Funds suit people who want exposure to the theme without picking individual names.

4. Secondaries

Early employees and early investors in private AI companies sometimes sell their shares before any IPO. Buying those shares — a secondary transaction — can be a way into a company whose primary rounds are shut. But secondaries come with real caveats: you often buy with limited information, the company may restrict or refuse transfers, pricing can be opaque, and you may pay a premium for scarce access. Where allowed, secondaries are a genuine route; they are not a shortcut around due diligence.

5. Pre-IPO vehicles

As a company matures towards a possible public listing, various vehicles offer late-stage or "pre-IPO" exposure — feeder funds, structured notes, or platforms pooling investors into a late round. These can shorten the wait to liquidity, but they layer on fees and intermediaries, and "pre-IPO" is a marketing phrase, not a guarantee that an IPO will ever happen. Read the structure carefully; the label tells you nothing about the terms.

The limits of public proxies

The liquid alternative is to buy public companies exposed to AI — the chipmakers, the cloud providers, the listed software firms building on top of the models. This is easy, cheap and sellable any day the market is open. It is also diluted: you are buying a large business with many other drivers, not a pure stake in the AI company you actually want. Public proxies are a reasonable way to own the theme broadly. They are not a way into the private rounds, and their prices already carry a great deal of AI optimism.

Why the biggest AI rounds are closed to ordinary investors

It is worth being blunt about this, because a lot of marketing implies otherwise. The largest AI companies do not need your money, and they know it. When demand for a round vastly exceeds the shares on offer, the company can be selective, and it chooses for strategic value: partners who provide compute or distribution, investors who bring credibility, backers who will support the next round too. A first-time outside investor with a modest cheque offers none of that.

There is also the legal wall. In most jurisdictions, private placements are restricted to accredited or professional investors — a status defined by wealth, income or experience. That rule exists to protect people from illiquid, high-risk instruments, and it does exclude most of the public from primary AI rounds by design.

The practical consequence is that when someone offers ordinary investors "access to OpenAI" or a similar name, you should slow down and ask exactly what is being sold. Sometimes it is a legitimate secondary or a well-structured feeder. Sometimes it is a thin layer of fees wrapped around a tenuous claim. The genuine article is rare, and it is never as frictionless as the pitch suggests.

The specific risks of AI investing

AI investments carry every risk of private investing, plus a few the current cycle sharpens. Take these seriously; they are the reason a good company can still be a poor investment at the wrong price.

• Valuations detached from revenue. Some AI companies are valued on what they might become, not what they earn today. When a price assumes a future that has not arrived, any disappointment reprices it sharply.
• Compute cost and cash burn. Training and serving frontier models is extraordinarily expensive. Many AI companies burn cash at a rate that depends on continuous fundraising. If capital markets tighten, the burn does not.
• Model commoditisation. Capabilities are converging and the price of inference keeps falling. A moat built on model quality alone can erode as competitors — including well-funded open-weight efforts — catch up.
• Regulation and legal exposure. Copyright, data, safety and competition rules are still forming. A single ruling or law can reshape the economics of an entire category.
• Concentration. Much of the value, and much of the capital, sits in a handful of names. That crowding cuts both ways — it can lift and it can unwind together.
• Illiquidity. Private AI shares can take many years to become sellable, if ever. Your money is committed to an exit you do not control.
• Hype cycles. Expectations inflate ahead of reality and then correct. Buying at the peak of a hype wave is how good long-term themes still lose money in the short term.

None of this is an argument against investing in AI. It is an argument for pricing those risks in, and for sizing the position as capital you can afford to lock away and, in a bad case, lose entirely.

How to evaluate an AI startup

Strip away the label and an AI company is still a company. The questions that decide whether it is worth backing are old ones, applied to a fast-moving field.

• Moat. What stops a better-funded competitor from doing this next quarter? If the answer is "our model is slightly better," that is a thin moat in a field where quality converges fast. Durable moats tend to come from proprietary data, workflow lock-in, or distribution.
• Data. Does the company have access to data others cannot easily replicate, and the right to use it? Data advantage is one of the few moats that compounds.
• Distribution. Who is putting this product in front of users, and at what cost? A strong distribution channel — an existing platform, an enterprise relationship — often matters more than a marginal model edge.
• Unit economics of inference. What does it cost to serve one customer, and is that cost falling faster than the price the company can charge? An AI product that loses money on every query at scale is a subsidy, not a business, until proven otherwise.
• Team. Can this team ship, hire and adapt as the field moves under them? In a market this fast, the ability to change direction well is itself a moat.

If a company cannot answer these plainly, the AI label does not rescue it. If it can, the label is almost beside the point — you have found a good business that happens to work in the most important field of the moment.

A grounded closing

Investing in AI startups in 2026 is worth doing carefully and badly worth doing carelessly. The theme is real, the best companies are genuinely remarkable, and the access is genuinely hard. Those three facts sit together and none of them cancels the others out.

So be clear-eyed. Decide which door you can actually get through. Price in the fees and the illiquidity. Size the position as money you could lose. And judge each company on its moat, data, distribution, economics and team — not on the excitement around the acronym. Do that, and AI becomes one more field where patient, informed, at-risk capital can do well. Skip it, and it becomes one more cycle where the story outran the diligence. Capital is at risk, and the only reliable edge is the willingness to look plainly at what you are buying.